Clinical efficacy was evaluated using the Psoriasis Area and Severity Index (PASI), along with metabolic indicators such as ...

A decade-long study finds that obesity is associated with a significantly increased risk for biologic treatment failure in ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

A RECENT study has highlighted key biological and clinical factors linked to resistance to biologic therapies in patients ...

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

Several characteristics, including BMI and Charlson Comorbidity Index, were associated with super response to biologics in patients with psoriasis.

Patients with generalized pustular psoriasis (GPP) experience frequent flares, and treatment alterations of off-label agents are frequently observed.

Biologics received were etanercept (n = 815 ... with favorable safety profiles in clinical practice.” Data on psoriasis severity scores and HZ vaccination rates were not available.

A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable ...

Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and more frequent adverse events. The study used the Dutch BioCAPTURE ...

Art Garfunkel discusses his experience living with psoriasis as part of Sun Pharma’s I LUV YA for The Long Haul campaign.

The psoriasis pipeline possesses some drugs in mid- and late-stage development to be approved in the near future. The emerging landscape holds a dive ...